Log In
Print
BCIQ
Print
Print this Print this
 

Zmapp

  Manage Alerts
Collapse Summary General Information
Company Mapp Biopharmaceutical Inc.
DescriptionCombination of 3 mAbs targeting Ebola glycoproteins GP1 and GP2
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationEbola
Indication DetailsTreat Ebola infection
Regulatory Designation
Partner Defyrus Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today